Researchers say findings help to bridge the structure of the genome to its function in managing how genes are turned on and off.

The combination of pembrolizumab and EVX-01, a personalized peptide-based neoantigen cancer vaccine, demonstrated activity in patients with advanced melanoma, according to phase 2 study results.